HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Sun Pharma Intelligence Report

Intelligence report

Intelligence Report · ~12 min read

Sun Pharma Intelligence Report

Generated from 2 signals · 2 evidence sources

Type

Company Intelligence Report

Generated

Jun 20, 2026

Confidence

Moderate Confidence · 66%

Evidence

12 items

Sources

5

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Sun Pharma maintains an active intelligence profile across Dermatology, Acne. 2 signals are linked with 0 investigate-priority items requiring leadership attention. Competitive pressure is low with moderate portfolio impact. Evidence coverage stands at 66% across 2 tracked sources. Highest-priority development: FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG). Regulatory precedent. Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Sun Pharma; the same agency is already in play for this signal, so precedent weight is higher.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. regulatory

    FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)

    Regulatory precedent may inform portfolio positioning

    View detail
  2. regulatory

    FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)

    Regulatory precedent may inform portfolio positioning

    View detail
  3. regulatory

    FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)

    Regulatory precedent may inform portfolio positioning

    View detail
  4. regulatory

    FDA AP — ABSORICA LD (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  5. regulatory

    FDA AP — ABSORICA (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  6. regulatory

    FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)

    Regulatory precedent may inform portfolio positioning

    View detail
  7. regulatory

    Macau-Union Pharmaceutical Limited - 724506 - 05/29/2026

    Regulatory precedent may inform portfolio positioning

    View detail
  8. regulatory

    Hubei Gedian Humanwell Pharmaceutical Co., Ltd. - 725591 - 06/03/2026

    Regulatory precedent may inform portfolio positioning

    View detail
  9. regulatory

    FDA AP — ABSORICA (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  10. regulatory

    FDA AP — ABSORICA LD (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Opportunity score 34 with buyer quality 3 (Low Priority). Competitive pressure: Low. Portfolio impact: Moderate.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — ABSORICA LD (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — ABSORICA (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Macau-Union Pharmaceutical Limited - 724506 - 05/29/2026

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Hubei Gedian Humanwell Pharmaceutical Co., Ltd. - 725591 - 06/03/2026

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — ABSORICA (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — ABSORICA LD (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • FDA Accepts Supplement Application for Absorica by Sun Pharma

    Dermatology · Acne

  • FDA Accepts Supplement for ABSORICA LD by Sun Pharma

    Dermatology · Acne

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.